abstract |
The present invention relates to methods for reducing LDL-cholesterol levels in blood comprising the administration of a combination of at least two different anti- PCSK9 antagonist antibodies or an anti-PCSK9 antagonist antibody (e.g., bispecific or bifunctional antibody) directed to different epitopes of PCSK9 protein. The subject single or combination treatment can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including hypercholesterolemia, dyslipidemia, hyperlipidemia, atherosclerosis, acute coronary syndrome and, more generally, cardiovascular disease (CVD). |